ADPT (Adaptive Biotechnologies) Float Percentage Of Total Shares Outstanding: 79.20% (As of Jun. 30, 2026)


ADPT Adaptive Biotechnologies Corp ADPT
67 GF Score
Price $21.40
GF Value $10.06
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Adaptive Biotechnologies Float Percentage Of Total Shares Outstanding?

Adaptive Biotechnologies ADPT +2.10% 67 Float Percentage Of Total Shares Outstanding is 79.20% as of Jun. 30, 2026. GuruFocus rates ADPT with a GF Score™ of 67/100 and a GF Value™ of $10.06 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Adaptive Biotechnologies's float shares is 126.75 Mil. Adaptive Biotechnologies's total shares outstanding is 160.04 Mil. Adaptive Biotechnologies's float percentage of total shares outstanding is 79.20%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Adaptive Biotechnologies's Insider Ownership is 6.63%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Adaptive Biotechnologies's Institutional Ownership is 102.15%.

ADPT
67GF Score
Adaptive Biotechnologies Corp ADPT
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adaptive Biotechnologies Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Adaptive Biotechnologies's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=126.75/160.04
=79.20%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 79.20% mean?
Adaptive Biotechnologies (ADPT) has a Float Percentage Of Total Shares Outstanding of 79.20% as of Jun. 30, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Adaptive Biotechnologies and its competitors.
Is Adaptive Biotechnologies' Float Percentage Of Total Shares Outstanding too high?
Adaptive Biotechnologies' current Float Percentage Of Total Shares Outstanding is 79.20%. Overall, Adaptive Biotechnologies has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Adaptive Biotechnologies' Float Percentage Of Total Shares Outstanding compare to GRAL and WGS?
Adaptive Biotechnologies' Float Percentage Of Total Shares Outstanding of 79.20% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Medical Diagnostics & Research company?
A good Float Percentage Of Total Shares Outstanding depends on the Medical Diagnostics & Research industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Adaptive Biotechnologies and its competitors. Adaptive Biotechnologies's current Float Percentage Of Total Shares Outstanding is 79.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adaptive Biotechnologies stock overvalued right now?
Based on GuruFocus' analysis, Adaptive Biotechnologies (ADPT) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.06, compared to a current price of $21.40 — trading 112.7% above its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 79.20%. Adaptive Biotechnologies' overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Adaptive Biotechnologies (ADPT), the current Float Percentage Of Total Shares Outstanding is 79.20% as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Adaptive Biotechnologies (ADPT) Overvalued in 2026?

Based on GuruFocus' analysis, Adaptive Biotechnologies stock appears to be overvalued. The current stock price of $21.40 is trading 112.7% above its estimated GF Value™ of $10.06. GuruFocus considers Adaptive Biotechnologies to be Significantly Overvalued.

Key valuation signals for ADPT:

  • Float Percentage Of Total Shares Outstanding: 79.20%
  • GF Value™: $10.06 vs. price of $21.40 (112.7% above fair value)
  • GF Score™: 67/100 with 5 warning signs

No single metric tells the full story. See the ADPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Adaptive Biotechnologies Business Description

Other Exchanges 1HM:Germany
Address 1165 Eastlake Avenue East, Seattle, WA, USA, 98109
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
67GF Score

Get the complete analysis for ADPT

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.40
Price
$10.06
GF Value